Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. decreased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 14.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 289,838 shares of the company’s stock after selling 49,894 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned 0.14% of Hims & Hers Health worth $2,580,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. CM Wealth Advisors LLC acquired a new stake in Hims & Hers Health in the second quarter valued at approximately $25,000. Point72 Middle East FZE acquired a new stake in Hims & Hers Health in the fourth quarter valued at approximately $29,000. Captrust Financial Advisors grew its position in Hims & Hers Health by 1,827.4% in the first quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock valued at $36,000 after acquiring an additional 6,414 shares in the last quarter. Harbour Investments Inc. grew its position in Hims & Hers Health by 427.9% in the third quarter. Harbour Investments Inc. now owns 6,995 shares of the company’s stock valued at $44,000 after acquiring an additional 5,670 shares in the last quarter. Finally, Belpointe Asset Management LLC acquired a new stake in shares of Hims & Hers Health during the first quarter worth approximately $46,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on HIMS. Truist Financial raised their price target on shares of Hims & Hers Health from $10.00 to $13.00 and gave the stock a “hold” rating in a research report on Tuesday, February 27th. Guggenheim lifted their price objective on shares of Hims & Hers Health from $15.00 to $17.00 and gave the stock a “buy” rating in a report on Tuesday, February 27th. Imperial Capital upgraded Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 target price on the stock in a research note on Wednesday, February 28th. Leerink Partnrs reiterated a “market perform” rating on shares of Hims & Hers Health in a research note on Monday, February 26th. Finally, Piper Sandler raised their target price on Hims & Hers Health from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Tuesday, February 27th. Five equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $14.85.

Insider Activity at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $15.65, for a total transaction of $39,171.95. Following the transaction, the insider now directly owns 166,866 shares of the company’s stock, valued at $2,611,452.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, insider Soleil Boughton sold 2,503 shares of Hims & Hers Health stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $15.65, for a total transaction of $39,171.95. Following the transaction, the insider now directly owns 166,866 shares of the company’s stock, valued at $2,611,452.90. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36. The disclosure for this sale can be found here. Insiders have sold a total of 675,838 shares of company stock worth $8,487,125 over the last ninety days. 31.63% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Down 0.6 %

Shares of NYSE HIMS opened at $12.34 on Friday. Hims & Hers Health, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $17.16. The firm’s 50-day simple moving average is $13.47 and its 200 day simple moving average is $9.80. The stock has a market cap of $2.64 billion, a P/E ratio of -112.18 and a beta of 0.91.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.03. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The business had revenue of $246.60 million for the quarter, compared to analysts’ expectations of $245.84 million. During the same period in the previous year, the business earned ($0.05) earnings per share. The company’s revenue was up 47.4% on a year-over-year basis. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.1 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.